Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
ConclusionNivolumab appeared to be safe and effective in Taiwanese patients. These interim results suggest that nivolumab is a suitable treatment option for this population.Clinical trial registrationNCT02582125.
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | General Medicine | Lung Cancer | Men | Non-Small Cell Lung Cancer | Septic Shock | Study | Taiwan Health